Advertisement

Journal of Clinical Immunology

, Volume 15, Issue 6, pp 284–292 | Cite as

CpG DNA: A pathogenic factor in systemic lupus erythematosus?

  • Arthur M. Krieg
Special Article

Abstract

Systemic lupus erythematosus (SLE) is a multifactorial disease of unknown etiology. Characteristic features of SLE include (1) polyclonal B cell activation, (2) overexpression of the immune stimulatory cytokine interleukin-6 (IL-6), (3) defective tolerance to self antigens, and (4) production of anti-DNA antibodies (Ab). Bacterial infection has been suspected as a triggering factor for lupus. Bacterial DNA differs from vertebrate DNA in the frequency and methylation of CpG dinucleotides. These CpG motifs in bacterial DNA induce a variety of immune effects, including (1) polyclonal activation of murine and human B cells, (2) IL-6 secretion, and (3) resistance to apoptosis, thereby potentially allowing the survival of autoreactive cells. These results suggest that microbial DNA could therefore be a pathogenic factor in SLE. SLE patients have elevated levels of circulating plasma DNA which is reportedly enriched in hypomethylated CpGs. Genomic DNA is also hypomethylated in SLE. The purpose of this review is to summarize the immune effects of CpG motifs and to present the evidence for their possible involvement in the pathogenesis of SLE.

Key words

CpG systemic lupus erythematosus autoimmunity infection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lerner RA, Meinke W, Goldstein DA: Membrane-associated DNA in the cytoplasmism of diploid human lymphocytes. Proc Natl Acad Sci USA 68:1212–1216, 1971PubMedGoogle Scholar
  2. 2.
    Aggrarwal SK, Wagner RW, McAllister PK, Rosenberg B: Cellsurface-associated nucleic acid in tumorigenic cells made visible with platinum-pyrimidine complexes by electron microscopy. Proc Natl Acad Sci USA 72:928–932, 1975PubMedGoogle Scholar
  3. 3.
    Bennett RM, Gabor GT, Merritt MM: DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. J Clin Invest 76:2182–2190, 1985PubMedGoogle Scholar
  4. 4.
    Jaroszewski JW, Cohen JS: Cellular uptake of antisense oligodeoxynucleotides. Adv Drug Deliv Rev 6:235–250, 1991Google Scholar
  5. 5.
    Akhtar S, Shoji Y, Juliano RL: Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides.In Gene Regulation: Biology of Antisense RNA and DNA, RP Erickson, JG Izant, eds. New York, Raven Press, 1992, pp 133–145Google Scholar
  6. 6.
    Krieg AM: Uptake and localization of phosphodiester and chimeric oligodeoxynucleotides in normal and leukemic primary cells.In Delivery Strategies for Antisense Oligonucleotide Therapeutics, S Akhtar, ed. Boca Raton, FL, CRC Press, 1995, pp 177–190Google Scholar
  7. 7.
    Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474–3478, 1989PubMedGoogle Scholar
  8. 8.
    Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV: Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86:6454–6458, 1989PubMedGoogle Scholar
  9. 9.
    Zhao Q, Waldschmidt T, Fisher E, Herrera CJ, Krieg AM: Stage specific oligonucleotide uptake in murine bone marrow B cell precursors. Blood 84:3660–3666, 1994PubMedGoogle Scholar
  10. 10.
    Geselowitz DA, Neckers LM: Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radio-labeled crosslinker. Antisense Res Dev 2:17–26, 1992PubMedGoogle Scholar
  11. 11.
    Krieg AM, Gmelig-Meyling F, Gourley MF, Kisch WJ, Chrisey LA, Steinberg AD: Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res Dev 1:161–171, 1991PubMedGoogle Scholar
  12. 12.
    Agrawal S, Tesnamani J, Galbraith W, Tang J: Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28:7–16, 1995PubMedGoogle Scholar
  13. 13.
    Chused TM, Steinberg AD, Talal N: The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immunol 12:465–476, 1972PubMedGoogle Scholar
  14. 14.
    Rumore P, Muralidhar B, Lin M, Lai C, Steinman CR: Haemodialysis as a model for studying endogenous plasma DNA: Oligonucleosome-like structure and clearance. Clin Exp Immunol 90: 56–62, 1992PubMedGoogle Scholar
  15. 15.
    Emlen W, Mannik M: Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. Clin Exp Immunol 56:185–192, 1984PubMedGoogle Scholar
  16. 16.
    Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL: Biodistribution and metabolism of internally3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45:932–943, 1994PubMedGoogle Scholar
  17. 17.
    Agrawal S, Temsaman J, Tang JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595–7599, 1991PubMedGoogle Scholar
  18. 18.
    Cossum PA, Truong L, Owens SR, Markham PM, Shea JP, Crooke ST: Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 269:89–94, 1994PubMedGoogle Scholar
  19. 19.
    Zhao Q, Matson S, Herrara CJ, Fisher E, Yu H, Waggoner A, Krieg AM: Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3:53–66, 1993PubMedGoogle Scholar
  20. 20.
    Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, Schlick E, Ruffmann R, Wiltrout RH, Chirigos MA: Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res 45:1058–1065, 1985PubMedGoogle Scholar
  21. 21.
    Wiltrout RH, Salup RR, Twilley TA, Talmadge JE: Immunomodulation of natural killer activity by polyribonucleotides. J Biol Resp Mod 4:512–517, 1985Google Scholar
  22. 22.
    Krown SE: Interferons and interferon inducers in cancer treatment. Semin Oncol 13:207–217, 1986PubMedGoogle Scholar
  23. 23.
    Ewel CH, Urba SJ, Kopp WC, Smith II JW, Steis RG, Rossio JL, Longo DL, Jones MJ, Alvord WG, Pinsky CM, Beveridge JM, McNitt KL, Creekmore SP: Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: Clinical and immunological effects. Cancer Res 52:3005–3010, 1992PubMedGoogle Scholar
  24. 24.
    Tokunaga T, Yamamoto S, Namba K: A synthetic single-stranded DNA, poly(dG,dC), induces interferon-α/β and -γ, augments natural killer activity, and suppresses tumor growth. Jpn J Cancer Res 79:682–686, 1988PubMedGoogle Scholar
  25. 25.
    Messina JP, Gilkeson GS, Pisetsky DS: The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol 147: 148–157, 1993PubMedGoogle Scholar
  26. 26.
    Feldbush TL, Ballas ZK: Lymphokine-like activity of 8-mercaptoguanosine: Induction of T and B cell differentiation. J Immunol 134:3204, 1985PubMedGoogle Scholar
  27. 27.
    Goodman MG: Mechanism of synergy between T cell signals and C8-substituted guanine nucleosides in humoral immunity: B lymphotropic cytokines induce responsiveness to 8-mercaptoguanosine. J Immunol 136:3335, 1986PubMedGoogle Scholar
  28. 28.
    Constant P, Davodeau F, Peyrat M-A, Poquet Y, Puzo G, Bonneville M, Fournie J-J: Stimulation of human cf T cells by nonpeptidic mycobacterial ligands. Science 264:267–270, 1994PubMedGoogle Scholar
  29. 29.
    Bell DA, Morrison B, VandenBygaart P: Immunogenic DNA-related factors. J Clin Invest 85:1487–1496, 1990PubMedGoogle Scholar
  30. 30.
    Hefenieder SH, Cornell KA, Brown LE, Bakke AC, McCoy SL, Bennett RM: Nucleosomes and DNA bind to specific cell-surface molecules on murine cells and induce cytokine production. Clin Immunol Immunopathol 63:245–251, 1992PubMedGoogle Scholar
  31. 31.
    Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T, Makiguchi N, Suganuma T: Antitumor activity of deoxyribonucleic acid fraction from mycobacterium bovis GCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 72:955–962, 1984PubMedGoogle Scholar
  32. 32.
    Yamamoto S, Kuramoto E, Shimada S, Tokunaga T: In vitro augmentation of natural killer cell activity and production of interferon-α/β and with deoxyribonucleic acid fraction from mycobacterium bovis BCG. Jpn J Cancer Res 79:866–873, 1988PubMedGoogle Scholar
  33. 33.
    Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T: DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36:983–997, 1992PubMedGoogle Scholar
  34. 33a.
    Yasmamoto S, Yamamoto T, Katoaka T, Kuramoto E, Yano O, Takunaga T: Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 148:4072–4076, 1992PubMedGoogle Scholar
  35. 34.
    Kuramoto E, Yano O, Kimura Y, Baba M, Makino T, Yamamoto S, Yamamoto T, Kataoka T, Tokunaga T: Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res 83:1128–1131, 1992PubMedGoogle Scholar
  36. 35.
    Messina JP, Gilkeson GS, Pisetsky DS: Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 147:1759–1764, 1991PubMedGoogle Scholar
  37. 36.
    Krieg AM, Gause WC, Gourley MF, Steinberg AD: A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol 143:2448–2451, 1989PubMedGoogle Scholar
  38. 37.
    Krieg AK, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky G, Klinman D: B cell activation by oligodeoxynucleotides that contain stem-loop motifs. Nature 374:546–549, 1995PubMedGoogle Scholar
  39. 38.
    Klinman D, Yi A-K, Connover J, Krieg AM: CpG motifs in bacterial DNA rapidly stimulate lymphocytes and NK cells to release cytokine (submitted)Google Scholar
  40. 39.
    Bird AP: CpG-rich islands and the function of DNA methylation. Nature 321:209–213, 1986PubMedGoogle Scholar
  41. 40.
    Han J, Zhu Z, Hsu C, Finley WH: Selection of antisense oligonucleotides on the basis of genomic frequency of the target sequence. Antisense Res Dev 4:53–65, 1994PubMedGoogle Scholar
  42. 41.
    Razin A, Friedman J: DNA methylation and its possible biologic roles. Prog Nucleic Acid Res Mol Biol 25:33–52, 1981PubMedGoogle Scholar
  43. 42.
    Cowdery JS, Chace JH, Krieg AM: Bacterial DNA induces in vivo interferon-γ production by NK cells and increases sensitivity to endotoxin (manuscript submitted)Google Scholar
  44. 43.
    Jakway JP, Unsinger WR, Gold MR, Mishell RI, DeFranco AL: Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products. J Immunol 137:2225–2231, 1986PubMedGoogle Scholar
  45. 44.
    Tsubata T, Wu J, Honjo T: B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 364:645–648, 1993PubMedGoogle Scholar
  46. 45.
    Iguchi-Ariga SMM, Schaffner W: CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 3:612–619, 1989PubMedGoogle Scholar
  47. 46.
    Manny N, Datta SK, Schwartz RS: Synthesis of IgM by cells of NZB and SWR mice and their crosses. J Immunol 122:1220, 1979PubMedGoogle Scholar
  48. 47.
    Moutsopoulos HM, Boehm-Truitt M, Kassan SS, Chused TM: Demonstration of activation of B lymphocytes in New Zealand Black mice at birth by an immunoradiometric assay for murine IgM. J Immunol 119:1639, 1977PubMedGoogle Scholar
  49. 48.
    Klinman DM: Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J Clin Invest 86:1249, 1990PubMedGoogle Scholar
  50. 49.
    Lahat N, Aghai E, Maroun B, Kinarty A, Quitt M, Froom P: Increased spontaneous secretion of IL-6 from B cells of patients with B chronic lymphatic leukaemia (B-CLL) and autoimmunity. Clin Exp Immunol 85:302–306, 1991PubMedGoogle Scholar
  51. 50.
    Finck BK, Chan B, Wofsy D: Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 94:585–591, 1994PubMedGoogle Scholar
  52. 51.
    Steinman CR: Free DNA in serum and plasma from normal adults. J Clin Invest 56:512–515, 1975PubMedGoogle Scholar
  53. 52.
    Dennin RH: DNA of free and complexed origin in human plasma: Concentration and length distribution. Klin Wochenschur 57:451–456, 1979Google Scholar
  54. 53.
    Fournie GJ, Dueymes J-M, Gayral-Taminh M, Pourrat JP, Mignon-Conte M, Conte JJ: Anti-DNA antibody idiotypes in SLE. Lancet 821–822, 1984Google Scholar
  55. 54.
    McCoubrey-Hoyer A, Okarma TB, Holman HR: Partial purification and characterization of plasma DNA and its relation to disease activity in systemic lupus erythematosus. Am J Med 77:23–33, 1984Google Scholar
  56. 55.
    Raptis L, Menard HA: Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J Clin Invest 66:1391–1399, 1980PubMedGoogle Scholar
  57. 56.
    Bennett RM, Peller JS, Merritt MM: Defective DNA-receptor function in systemic lupus erythematosus and related diseases: Evidence for an autoantibody influencing cell physiology. Lancet II:186–188, 1986Google Scholar
  58. 57.
    Bennett RM, Kotzin BL, Merritt MJ: DNA receptor dysfunction in systemic lupus erythematosus and kindred disorders. J Exp Med 166:850–863, 1987PubMedGoogle Scholar
  59. 58.
    Compton LJ, Steinberg AD, Sano H: Nuclear DNA degradation in lymphocytes of patients with systemic lupus erythematosus. J Immunol 133:213–216, 1984PubMedGoogle Scholar
  60. 59.
    Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152:3685–3692, 1994PubMedGoogle Scholar
  61. 60.
    Rumore PM, Steinman CR: Endogenous circulating DNA in systemic lupus erythematosus. J Clin Invest 86:69–74, 1990PubMedGoogle Scholar
  62. 61.
    Sano H, Morimoto C: DNA isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content. J Immunol 128:1341–1345, 1982PubMedGoogle Scholar
  63. 62.
    Van Helden PD: Potential Z-DNA-forming elements in serum DNA from human systemic lupus erythematosus. J Immunol 134:177–179, 1985PubMedGoogle Scholar
  64. 63.
    Sano H, Takai O, Harata N, Yoshinaga K, Kodama-Kamada I, Sasaki T: Binding properties of human anti-DNA antibodies to cloned human DNA fragments. Scand J Immunol 30:51–63, 1989PubMedGoogle Scholar
  65. 64.
    Krapf F, Herrmann M, Leitmann W, Kalden JR: Antibody binding of macromolecular DNA and RNA in the plasma of SLE patients. Clin Exp Immunol 75:336–342, 1989PubMedGoogle Scholar
  66. 65.
    Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M: Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arth Rheum 33:1665–1673, 1990Google Scholar
  67. 66.
    Isenberg DA, Ehrenstein MR, Longhurst C, Kalsi JK: The origin, sequence, structure, and consequences of developing anti-DNA antibodies. A human perspective. Arth Rheum 37:169–180, 1994Google Scholar
  68. 67.
    Li JZ, Steinman CR: Plasma DNA in systemic lupus erythematosus. Arth Rheum 32:726–733, 1989Google Scholar
  69. 68.
    Steinman CR: Circulating DNA in systemic lupus erythematosus. J Clin Invest 73:832–841, 1984PubMedGoogle Scholar
  70. 69.
    Terada K, Okuhara E, Kawarada Y: Antigen DNA isolated from immune complexes in plasma of patients with systemic lupus erythematosus hybridizes with the Escherichia coli lac Z gene. Clin Exp Immunol 85:66–69, 1991PubMedGoogle Scholar
  71. 70.
    Terada K, Okuhara E, Kawarada Y, Hirose S: Demonstration of extrinsic DNA from immune complexes in plasma of a patient with systemic lupus erythematosus. Biochem Biophys Res Comm 174:323–330, 1991PubMedGoogle Scholar
  72. 71.
    Cornacchia E, Golbus J, Baybaum J, Strahler J, Hanash S, Richardson B: Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140:2197–2200, 1988PubMedGoogle Scholar
  73. 72.
    Quddus J, Johnson KJ, Gavalchin J, Amento EP, Chrisp CE, Yung RL, Richardson BC: Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92:38–53, 1993PubMedGoogle Scholar
  74. 73.
    Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC: Mechanisms of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154:3025–3035, 1995PubMedGoogle Scholar
  75. 74.
    Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M: Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 349:331–334, 1991PubMedGoogle Scholar
  76. 75.
    Chen C, Nagy Z, Radic MZ, Hardy RR, Huszar D, Camper SA, Weigert M: The site and stage of anti-DNA B-cell deletion. Nature 376:252–255, 1995Google Scholar
  77. 76.
    Gilkeson GS, Grudier JP, Karounos DG, Pisetsky DS: Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. J Immunol 142:1482–1486, 1989PubMedGoogle Scholar
  78. 77.
    Gilkeson GS, Pippen AMM, Pisetsky DS: Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J Clin Invest 95:1398–1402, 1995PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Arthur M. Krieg
    • 1
    • 2
  1. 1.Department of Internal MedicineUniversity of Iowa College of MedicineIowa City
  2. 2.Department of Veterans AffairsIowa City

Personalised recommendations